NAVIGEN, INC.

Basic Information

383 Colorow Drive
SALT LAKE CITY, UT, 84108-1201

http://www.nvgn.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 792046224
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 19


  1. Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr

    Amount: $1,502,644.00

    DESCRIPTION (provided by applicant): In spite of remarkable progress in management of rheumatoid arthritis (RA), a devastating autoimmune disease that affects 2.5 million Americans causing chronic inf ...

    SBIR Phase II 2014 Department of Health and Human Services
  2. CT-based Biomarker for Diagnosis of COPD Phenotypes and Disease Progression

    Amount: $145,269.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) affects approximately 1.3 million adults in the United States and up to 1.5% of the population worldwide. In its progressive form the dis ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Identification of novel small molecule inhibitors of Arf6 for the treatment of va

    Amount: $150,640.00

    DESCRIPTION (provided by applicant): Age-Related Macular Degeneration is the most common cause of legal blindness in people over 60, affecting an estimated 1.6 million patients. Additionally, over 400 ...

    SBIR Phase I 2013 Department of Health and Human Services
  4. Therapeutic D-peptide Inhibitor of HIV Entry

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): With 33 million people living with HIV/AIDS (including 1.2 million in the US), and 1.8 million AIDS-related deaths annually, HIV/AIDS remains a formidable global e ...

    SBIR Phase II 2013 Department of Health and Human Services
  5. Protease-resistant D-peptide inhibitors of RSV entry

    Amount: $592,068.00

    DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the major cause of severe lower respiratory tract infections in children and infants, affecting an estimated 64 million people ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Protease-resistant D-peptide Inhibitors of Ebola Virus Entry

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Ebola virus (EboV) is a filovirus that causes a highly deadly hemorrhagic fever in humans and non-human primates. Since its discovery in central Africa in 1976, th ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Novel Therapeutic Approach for Sepsis: Blocking the Vascular Response to Cytokine

    Amount: $557,531.00

    DESCRIPTION (provided by applicant): In the United States alone, sepsis affects approximately 700,000 patients and leads to death of over 210,000 people per year. Sepsis is a clinical syndrome that re ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. Therapeutic D-peptide Inhibitor of HIV entry

    Amount: $299,392.00

    DESCRIPTION (provided by applicant): HIV/AIDS remains a formidable global epidemic with 33 million infections worldwide, including over 1 million patients in the US. In 2008, there were 2.7 million ne ...

    SBIR Phase I 2011 Department of Health and Human Services
  9. Novel Therapeutic Approach to Acute Lung Injury

    Amount: $1,121,436.00

    DESCRIPTION (provided by applicant): In our Phase 1 application, we described an endothelial specific receptor, Robo4, that is expressed in mature vessels and is upregulated following endothelial inju ...

    SBIR Phase II 2010 Department of Health and Human Services
  10. SLIT2N for the treatment of influenza-induced acute respiratory distress

    Amount: $591,856.00

    DESCRIPTION (provided by applicant): Influenza infection leads to a cytokine storm as the host's immune system fights the virus. This combination of immunity factors has the unfortunate side effect of ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government